Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000950170-25-110311·Atara Biotherapeutics, Inc.
Schedule 13D ownership disclosure
ATARA BIOTHERAPEUTICS INC
Common Stock · CUSIP: 046513107
Event date: 2025-08-15
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Panacea Innovation LimitedReported CIK 0002010692
Shares: 1,712,900 · Class: 20.0%
- Panacea Venture Healthcare Fund II, L.P.Reported CIK 0001869939
Shares: 1,405,000 · Class: 20.0%
- Panacea Venture Healthcare Fund II GP Company, Ltd.
Shares: 1,405,000 · Class: 20.0%
- Panacea Opportunity Fund I, L.P.Reported CIK 0001869966
Shares: 307,900 · Class: 4.2%
- Panacea Opportunity Fund I GP Company, Ltd.
Shares: 307,900 · Class: 4.2%
- James HuangReported CIK 0001573160
Shares: 1,712,900 · Class: 20.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-110311
- Form type
- SCHEDULE 13D/A
- Filer
- Atara Biotherapeutics, Inc.
- CIK
- CIK 1604464
- Filed
- Aug 19, 2025
- Reporting period
- Aug 15, 2025
- Description
- Schedule 13D beneficial ownership